AnaSpec has introduced its latest development in novel solutions for amyloid-related research - the new SensoLyte 520 beta-secretase assay kit
Beta-secretase catalyses a key step in the production of beta-amyloid peptides seen accumulated in senile plagues of Alzheimer's disease (AD) brains.
In order to facilitate high throughput screening of AD drug candidates, AnaSpec has developed a new SensoLyte 520 beta-secretase assay kit using a fluorescence resonance energy transfer (Fret) peptide, HiLyte Fluor 488-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys(QXL 520)-OH.
The sequence of this Fret peptide is derived from the beta-secretase cleavage site of beta-amyloid precursor protein(APP) with Swedish mutation.
This mutation enhances the susceptibility of APP to beta-secretase and results in an early onset of AD.
This assay has good sensitivity (0.03mU/ml) with a signal-to-background ratio >10 after a 30-minute incubation.
This homogeneous assay can be used to continuously monitor product formation.
Validated with known inhibitors, the IC50 value for one of the inhibitors determined with SensoLyte 520 beta-secretase assay kit was consistent with published data.
